Dr. Scott Gottleib just did another interview on the thought process of the FDA looking at a drug efficacy based upon the molecularity instead of an organ or tumor location. In the right hands, this would be a pathway for Bavituximab. Meanwhile, Tustin considers a strategic plan taking a poster to a convention. Just pathetic how the only thing they can monetize is their excessive paychecks-compliments of shareholders.
Market Data 
Markets 
